Synthetic gastric pentadecapeptide (research-stage healing agent)
Body Protection Compound-157
A healing-focused peptide with extensive preclinical recovery data but very limited controlled human evidence.
- Evidence:
- Limited human evidence
- Status:
- Not FDA-approved
- Reviewed:
- 2026-08-03
Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157
What is Body Protection Compound-157?
A healing-focused peptide with extensive preclinical recovery data but very limited controlled human evidence.
This profile is educational. It organizes publicly discussed research context for Body Protection Compound-157 and related naming aliases — it is not a treatment guide.
Proposed mechanism
Proposed modulation of growth factor signaling (VEGF, FAK-paxillin), nitric oxide pathways, and cytoprotection in tendon, muscle, and GI tissue.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
BPC-157 is among the most discussed recovery peptides. Animal studies report accelerated healing of tendons, ligaments, and GI mucosa. Human randomized trials are sparse; much use is anecdotal or outside peer-reviewed literature. WADA prohibits BPC-157. Regulatory status is not FDA approved. Nasal bioavailability for many peptides including BPC-157 is poorly characterized in humans.
Key uncertainties
- Translation from animal models
- Human dose-response unknown for clinical contexts
Research areas being studied
- Tendon/ligament repair
- GI mucosal protection
- Soft tissue injury research
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Insufficient systematic human AE data
- Anecdotal reports vary
Additional risks & considerations
- Unproven human efficacy
- Unregulated product purity
- Unknown long-term safety
Regulatory status
Not FDA-approved
Not FDA approved; prohibited in sport (WADA S0).
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Body Protection Compound-157?
A healing-focused peptide with extensive preclinical recovery data but very limited controlled human evidence.
How does Body Protection Compound-157 work (proposed mechanism)?
Proposed modulation of growth factor signaling (VEGF, FAK-paxillin), nitric oxide pathways, and cytoprotection in tendon, muscle, and GI tissue.
What is Body Protection Compound-157 being researched for?
Body Protection Compound-157 has been discussed in research contexts including: Tendon/ligament repair, GI mucosal protection, Soft tissue injury research.
What does current evidence say about Body Protection Compound-157?
Limited human evidence. BPC-157 is among the most discussed recovery peptides. Animal studies report accelerated healing of tendons, ligaments, and GI mucosa. Human randomized trials are sparse; much use is anecdotal or outside peer-reviewed literature. WADA prohibits BPC-157. Regulatory status is not FDA approved. Nasal bioavailability for many peptides including BPC-157 is poorly characterized in humans.
What safety considerations are noted for Body Protection Compound-157?
Reported or discussed considerations include: Insufficient systematic human AE data; Anecdotal reports vary; Unproven human efficacy; Unregulated product purity; Unknown long-term safety. This is educational information, not medical advice.
Is Body Protection Compound-157 FDA approved?
Not FDA-approved. Not FDA approved; prohibited in sport (WADA S0).
References & sources
- Sikiric P et al. (2018). Stable gastric pentadecapeptide BPC 157 in wound healing — Curr Pharm Des. Evidence type: review.
Prefer interactive tools? Open the PepGuide library entry for Body Protection Compound-157 or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.